Saturday November 21 2009 | Biotechnology feed | All feeds
|
|
|
News Articles on OncoGenex Pharmaceuticals, Inc.OncoGenex Reports Third Quarter 2009 Financial ResultsConference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - On OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial ResultsBOTHELL, WA and VANCOUVER Nov. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will anno OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences CategoryBOTHELL, WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that Scott Cormack, pre FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line ChemotherapyBOTHELL, WA, and VANCOUVER, Oct. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known OncoGenex Pharmaceuticals to Webcast Presentations at September Investor ConferencesBOTHELL, WA and VANCOUVER, Sept. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company will we OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder CancerBOTHELL, WA and VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the first patient OncoGenex Reports Second Quarter 2009 Financial Results
Conference Call on Thursday, August 6, 2009 at 4:30 p.m. Eastern Time
BOTHELL, WA, and VANCOUVER, Aug. 6 /PRNewswire-First OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial ResultsBOTHELL, WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company will announce OncoGenex Pharmaceuticals Added to Russell IndexesBOTHELL, WA, and VANCOUVER, June 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed OncoGenex Pharmaceuticals Files Shelf Registration StatementBOTHELL, WA and VANCOUVER, June 26 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has filed a shel OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate CancerBOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has re OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate CancerWebcast at 7:10 p.m. Eastern Time Today BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009BOTHELL, WA and VANCOUVER, May 27 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will hol OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual MeetingBOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that final survival data OncoGenex Reports First Quarter Financial ResultsConference Call on Thursday, May 7, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, May 7 /PRNewswire-FirstCall/ - OncoGe OncoGenex Pharmaceuticals to Release First Quarter Financial ResultsBOTHELL, WA and VANCOUVER, April 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company's first OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
FDA confirms durable pain palliation as an acceptable primary endpoint
for a regulatory submission in support of market approval
http://www.bioportfolio.com/news/OncoGenex_Receives_Confirmation_from_FDA_on_the.html - Tuesday April 28 2009 OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009Conference Call on Wednesday, March 11, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, March 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009BOTHELL, WA and VANCOUVER, March 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung CancerBOTHELL, WA, and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the two-year survival ra OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
First-line trial currently shows median overall survival of 27.5 months
for OGX-011 in combination with docetaxel and prednisone and a |
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
